Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Chemotherapy with Avastin in Advanced Non-Squamous NSCLC
NCT00655850Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2008
- Primary completion
- Sep 2015
- Countries
- 1
- Sponsor
- University of Alabama at Birmingham
- Modality
- Monoclonal Antibodies
- Drugs
- bevacizumab
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by University of Alabama at Birmingham. Primary endpoint: Progression-Free Survival at 24 months. Started Mar 2008; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Paclitaxel and Gemcitabine + Avastin
Metronomic chemotherapy with paclitaxel and gemcitabine plus Avastin.
03
Endpoints
Primary
Progression-Free Survival
Secondary
Number of Participants With Adverse Events
Overall Survival
Objective Response Rate
Beyond the preview
Go deeper on NCT00655850.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00655850.